Daniel J Olson - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Daniel J Olson

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

Melanoma Research|November 10, 2020

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic targetRiyue Bao, Oliver Surriga, Daniel J Olson, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in MelanomaDaniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.

Cancer Research Communications|November 26, 2025

Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid TumorsBenjamin T Cooper, Wade T Iams, David B Page, et al.

Pageof 4

Search research articles

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

Melanoma Research|November 10, 2020

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic targetRiyue Bao, Oliver Surriga, Daniel J Olson, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in MelanomaDaniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.

Cancer Research Communications|November 26, 2025

Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid TumorsBenjamin T Cooper, Wade T Iams, David B Page, et al.

Pageof 4